These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9604303)

  • 21. Genetic analysis of the cytochrome P-45OIIC18 (CYP2C18) gene and a novel member of the CYP2C subfamily.
    Tsuneoka Y; Matsuo Y; Okuyama E; Watanabe Y; Ichikawa Y
    FEBS Lett; 1996 Apr; 384(3):281-4. PubMed ID: 8617372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population.
    Kubota T; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1996 Dec; 60(6):661-6. PubMed ID: 8988068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cytochrome P450 2C19 gene polymorphism in four Chinese nationality populations].
    Zhang S; Dong Z; Tang L; Zhou Q; Wu Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):52-4. PubMed ID: 11836688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy.
    Odani A; Hashimoto Y; Otsuki Y; Uwai Y; Hattori H; Furusho K; Inui K
    Clin Pharmacol Ther; 1997 Sep; 62(3):287-92. PubMed ID: 9333104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese.
    Takakubo F; Kuwano A; Kondo I
    Pharmacogenetics; 1996 Jun; 6(3):265-7. PubMed ID: 8807668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2A6 genetic polymorphisms and liver microsomal coumarin and nicotine oxidation activities in Japanese and Caucasians.
    Inoue K; Yamazaki H; Shimada T
    Arch Toxicol; 2000 Jan; 73(10-11):532-9. PubMed ID: 10663384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
    Chang TK; Yu L; Goldstein JA; Waxman DJ
    Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism analysis of cytochrome P4502C19 in Chinese Uigur and Han populations.
    Niu CY; Luo JY; Hao ZM
    Chin J Dig Dis; 2004; 5(2):76-80. PubMed ID: 15612662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene.
    Warner SC; Finta C; Zaphiropoulos PG
    Mol Biol Evol; 2001 Oct; 18(10):1841-8. PubMed ID: 11557791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of allele and genotype frequencies of CYP2C9, CYP2C19 and VKORC1 in Iran.
    Azarpira N; Namazi S; Hendijani F; Banan M; Darai M
    Pharmacol Rep; 2010; 62(4):740-6. PubMed ID: 20885015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
    Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
    Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of CYP2C subfamily in a Japanese population.
    Ieiri I; Higuchi S
    J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448
    [No Abstract]   [Full Text] [Related]  

  • 36. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
    Brøsen K; de Morais SM; Meyer UA; Goldstein JA
    Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemistry and molecular biology of the human CYP2C subfamily.
    Goldstein JA; de Morais SM
    Pharmacogenetics; 1994 Dec; 4(6):285-99. PubMed ID: 7704034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.
    Xie HG; Stein CM; Kim RB; Wilkinson GR; Flockhart DA; Wood AJ
    Pharmacogenetics; 1999 Oct; 9(5):539-49. PubMed ID: 10591534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
    Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
    Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.